Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Mallinckrodt
Colorcon
McKinsey
Moodys

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR IOTHALAMATE SODIUM I-125


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Iothalamate Sodium I-125

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00270829 ↗ Renal Effects of Intrarenal Nesiritide Terminated University of Maryland Phase 4 2005-12-01 The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF.
NCT00270829 ↗ Renal Effects of Intrarenal Nesiritide Terminated University of Maryland, Baltimore Phase 4 2005-12-01 The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF.
NCT01836809 ↗ Nesiritide and Renal Function After the Total Artificial Heart Terminated Virginia Commonwealth University Phase 4 2013-04-01 The prevalence of renal dysfunction after implantation of the artificial heart is high. The infusion of exogenous B-type natriuretic peptide (BNP) after implantation of the total artificial heart (TAH) improves renal function in a sustained manner. The renal protective and hormone-modulating effects of nesiritide may be enhanced with ventriculectomy compared to heart failure surgery that leaves the native myocardium intact. The goal of this project is to determine the renal protective effects of nesiritide after implantation of a mechanical device.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iothalamate Sodium I-125

Condition Name

Condition Name for Iothalamate Sodium I-125
Intervention Trials
Renal Impairment 2
Cardiomyopathy 2
Congestive Heart Failure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Iothalamate Sodium I-125
Intervention Trials
Heart Failure 3
Renal Insufficiency 3
Cardiomyopathies 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Iothalamate Sodium I-125

Trials by Country

Trials by Country for Iothalamate Sodium I-125
Location Trials
United States 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Iothalamate Sodium I-125
Location Trials
Minnesota 4
Virginia 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Iothalamate Sodium I-125

Clinical Trial Phase

Clinical Trial Phase for Iothalamate Sodium I-125
Clinical Trial Phase Trials
Phase 4 2
Phase 2 1
Phase 1/Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Iothalamate Sodium I-125
Clinical Trial Phase Trials
Completed 2
Terminated 2
Enrolling by invitation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Iothalamate Sodium I-125

Sponsor Name

Sponsor Name for Iothalamate Sodium I-125
Sponsor Trials
Mayo Clinic 4
University of Maryland, Baltimore 1
Virginia Commonwealth University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Iothalamate Sodium I-125
Sponsor Trials
Other 7
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Harvard Business School
McKesson
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.